A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2016
At a glance
- Drugs Rocapuldencel-T (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 24 Mar 2016 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018, according to ClinicalTrials.gov record.
- 24 Mar 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018, according to ClinicalTrials.gov record.